BioCatalyst

ARGX — ARGENX SE catalysts

2 verified catalyst event(s) for ARGENX SE (ticker ARGX). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2027-03-01 — Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Ad
Phase 2/3 · Generalized Myasthenia Gravis
 ARGX ARGENX SE Efgartigimod IV ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With
Phase 2 · Systemic Sclerosis (SSc)
 ARGX ARGENX SE Efgartigimod PH20 SC ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.